Daily Archives: June 17, 2021
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
CDC now calls coronavirus Delta variant a ‘variant of concern’.
17 Jun, 2021 | 09:53h | UTCCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Guidance: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Commentary on Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.? #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.
17 Jun, 2021 | 09:49h | UTCCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Commentary on Twitter (thread – click for more)
Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell
— Hilda Bastian, PhD (@hildabast) June 16, 2021
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
17 Jun, 2021 | 09:39h | UTCNews release: Induced hypothermia after cardiac arrest did not improve survival – Lund University
Infographic: The TTM2 Trial – CanadianEM
Commentary: Hypothermia or Normothermia after Cardiac Arrest – NEJM Resident 360
Video: TTM2 Results Presentation Livestream – Critical Care Reviews
Commentary on Twitter (thread – click for more)
The #TTM2trial was published today in the @NEJM https://t.co/jccLB1MO64
Here’s a summary of what we did, what I think the trial means, and what next.@ttm2trial @nielsen_niklas @CritCareReviews @NEJM— Paul Young (@DogICUma) June 16, 2021
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Systematic review: Safety and effectiveness of metformin in patients with reduced renal function – safe and beneficial at a eGFR of 45 mL/min/1.73m2 or higher; possibly harmful at an eGFR of less than 30 mL/min/1.73m2.
17 Jun, 2021 | 09:37h | UTC
Commentary on Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Kamlesh Khunti (@kamleshkhunti) June 16, 2021
Review: chronic pelvic pain in women.
17 Jun, 2021 | 09:36h | UTCChronic Pelvic Pain in Women: A Review – JAMA (free for a limited period)
Audio clinical review: Diagnosis and Clinical Care of Women With Chronic Pelvic Pain
The authorship rows that sour scientific collaborations.
17 Jun, 2021 | 09:34h | UTCThe authorship rows that sour scientific collaborations – Nature